• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AstraZeneca PLC - American Depositary Shares (NQ:AZN)

    73.03 -2.33 (-3.09%)
    Streaming Delayed Price Updated: 12:51 PM EDT, Sep 25, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,448,127
    Open 74.57
    Bid (Size) 73.02 (2)
    Ask (Size) 73.04 (2)
    Prev. Close 75.36
    Today's Range 72.89 - 74.69
    52wk Range 61.24 - 82.41
    Shares Outstanding N/A
    Dividend Yield 1.41%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    United Kingdom The Worst European Country For Drug Prices: Eli Lilly CEO
    Eli Lilly CEO Dave Ricks criticizes UK drug pricing and rebate rules as pharma giants scale back investments, warning of fewer new medicines. 
    Via Benzinga
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer
    From AstraZeneca
    Via Business Wire

    Performance

    YTD
    +10.9%
    +10.9%
    1 Month
    -8.3%
    -8.3%
    3 Month
    +4.8%
    +4.8%
    6 Month
    +0.4%
    +0.4%
    1 Year
    -5.0%
    -5.0%

    More News

    Read More
    European Advisory Panel Recommends Two AstraZeneca Drugs For Approval
    Via Benzinga
    Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
    Via MarketMinute
    Topics Economy Intellectual Property
    AstraZeneca Says Asthma Drug Failed Trial In Smoker’s Disease
    Via Stocktwits
    Is the Market Bullish or Bearish on AstraZeneca?
    Via Benzinga
    Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    The Pharmaceutical Revolution: AI, Gene Therapies, and Obesity Drugs Reshape a Trillion-Dollar Market
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    Johnson & Johnson Unleashes Triple Threat: Bladder Cancer Breakthrough, Psoriasis Game-Changer, and Myasthenia Gravis Milestone Signal New Pharma Era
    Via MarketMinute
    Lilly's $5 Billion Virginia Investment: A Game Changer for GLP-1 and Oncology Drug Production
    Via MarketMinute
    Topics Artificial Intelligence Economy Government
    Eli Lilly Poised for Blockbuster Q3 2025 with Skyrocketing EPS and Revenue Projections
    Via MarketMinute
    Topics Artificial Intelligence Economy Intellectual Property
    Lilly's Oncology Momentum Soars: Olomorasib Gains Breakthrough Status, Jaypirca Achieves Landmark Clinical Successes
    Via MarketMinute
    AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol
    From AstraZeneca
    Via Business Wire
    AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial
    Via Benzinga
    Advancing Cancer Research Brings New Hope for Patients Worldwide
    Via Investor Brand Network
    Topics Artificial Intelligence Intellectual Property
    Advancing Cancer Research Brings New Hope for Patients Worldwide
    Via FinancialNewsMedia
    Topics Artificial Intelligence Intellectual Property
    SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis
    From AstraZeneca
    Via Business Wire
    GSK Stock Climbs After-Hours On $30B US Investment Pledge As Trump Pressures Big Pharma To Build In America
    Via Stocktwits
    Topics Artificial Intelligence Government World Trade
    AstraZeneca Puts Cambridge Expansion On Ice Adding Pressure On Starmer Ahead Of Trump Visit
    Via Benzinga
    Topics Government
    The Weight of Progress: A New Era Dawns for Anti-Obesity Drugs, Reshaping Markets and Health
    Via MarketMinute
    Merck's Exit Highlights UK Risks Losing Pharma Investment Amid Rising Costs
    Via Benzinga
    China-Tied Biotechs Zai Labs, BeOne Plunge On Rumored Executive Order
    Via Investor's Business Daily
    Topics Government
    FDA Expands Approval For AstraZeneca's Drug For Pediatric Patients With Rare Type Of Cancer
    Via Benzinga
    Trump's Biotech Playbook Ignites $350 Billion Investment Blitz
    Via Benzinga
    Topics ETFs Government
    AstraZeneca Lung Cancer Combo Extends Patient Survival By Years In Key Study
    Via Benzinga

    Frequently Asked Questions

    Is AstraZeneca PLC - American Depositary Shares publicly traded?
    Yes, AstraZeneca PLC - American Depositary Shares is publicly traded.
    What exchange does AstraZeneca PLC - American Depositary Shares trade on?
    AstraZeneca PLC - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for AstraZeneca PLC - American Depositary Shares?
    The ticker symbol for AstraZeneca PLC - American Depositary Shares is AZN on the Nasdaq Stock Market
    What is the current price of AstraZeneca PLC - American Depositary Shares?
    The current price of AstraZeneca PLC - American Depositary Shares is 73.03
    When was AstraZeneca PLC - American Depositary Shares last traded?
    The last trade of AstraZeneca PLC - American Depositary Shares was at 09/25/25 12:51 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.